Knock out biologic quant and quality on a tiny sample

Virtual or “siteless” clinical trials allow trial coordinators and patients to conduct clinical study visits via online video calls and collect data via handheld or wearable devices. In addition, virtual trials increase the size and diversity of the patient pool, accelerate recruiting, and generate more informative, clinically-relevant data that is accepted by regulatory agencies. However, moving from traditional to virtual trials presents challenges as clinical trial sponsors learn how to design, execute, and complete effective virtual trials. To assure success, trial sponsors need to better understand the digital tools and platforms used in virtual trials, how to manage the data collection they enable, and the pitfalls to avoid. In this webinar, Bernard Munos, a pioneering pharmaceutical industry innovator, and Transparency Life Sciences co-founder Dr. Tomasz Sablinski will provide an overview of the strategies leaders are finding helpful in adopting and adapting to virtual trials.

The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is becoming of higher importance.

Regenerative medicine has become a key focus worldwide and the number of stem cell therapy trials are rapidly increasing every year. Yet, large-scale and GMP-compliant stem cell manufacturing is still a major hurdle for clinical applications across the globe. In this webinar, we will show you how to implement GMP-compliant and scalable manufacturing of different adherent cell types, such as pluripotent stem cells and their derivatives, in the CliniMACS Prodigy® Adherent Cell Culture System.

Multi-Gene panel-based genetic testing has emerged as the standard of care for cancer genetic testing. This has led to the identification of TP53 mutations among individuals without classic personal or family histories of Li-Fraumeni syndrome. These mutations may be due to mosaicism, clonal hematopoiesis, or due to form fruste Li-Fraumeni syndrome. We will discuss how these findings are shaping clinical cancer genetics care and how they are leading to a re-evaluation of the epidemiology and penetrance of germline TP53 mutations.